The Expert Committee recommended the inclusion of oral levetiracetam on the core list of the EML and EMLc for the treatment of focal-onset and generalized-onset seizures in adults in children. The Committee also recommended the inclusion of parenteral levetiracetam on the complementary list of the EML and EMLc for use in the management of benzodiazepine-refractory status epilepticus. These recommendations were made based on evidence of effectiveness and safety, and in recognition of the need for treatment strategies for people with epilepsy to be individualized taking into account multiple factors including, but not limited to, pregnancy and patient preferences, seizure type, co-morbidities, and concomitant use of other medications. These recommendations are also aligned with expected recommendations in the updated WHO Mental Health Gap Action Programme (mhGAP) guidelines.